Abstract
Background: The prognostic significance of the antiapoptotic protein secretory clusterin overexpression in breast cancer is unclear. Patients and Methods: Secretory clusterin expression was explained in three hundred and fifty-two patients with breast cancer by immunohistochemistry. Clusterin overexpression was tested for correlation with overall survival (OS) and relapse-free survival (RFS). Results: The overall frequency of clusterin overexpression was 52% (178 out of 342) in breast cancer; 44% for in situ carcinomas and 53% for invasive cancer. Among fifty-six patients with tumor recurrence, clusterin overexpression was found in 74% (14 out of 19) in breast cancer <T2 stage and 51% (19 out of 37) in ≥T2 stage breast cancer. The Kaplan-Meier analysis revealed that clusterin overexpression was a prognostic factor for RFS in breast cancer <T2 stage (mean RFS, 79.8 vs. 73.5 months, p=0.044). Conclusion: Our results suggest that clusterin overexpression might be a predictive factor for recurrence in <T2 stage breast cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 3909-3912 |
| Number of pages | 4 |
| Journal | Anticancer Research |
| Volume | 29 |
| Issue number | 10 |
| Publication status | Published - Oct 2009 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Breast
- Carcinoma
- Clusterin
- Relapse-free survival
Fingerprint
Dive into the research topics of 'Clusterin overexpression and relapse-free survival in breast cancer'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver